Involving Producing Or Treating Antigen Or Hapten Patents (Class 436/543)
  • Patent number: 10196671
    Abstract: The present invention discloses an assay method for the detection of viable microbial cells in a sample, the assay method comprising the steps of: i) adding an ATP degrading enzyme to a sample suspected of containing viable microbial cells to substantially degrade any extracellular ATP in the sample; ii) adding a phosphate containing compound to the sample to substantially halt action of the ATP degrading enzyme; and iii) subjecting the sample to a detection assay to establish the level of undegraded ATP in the sample to provide an indication of the level of viable microbial cells in the sample.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: February 5, 2019
    Assignee: 3M Innovative Properties Company
    Inventors: Gerald J. Bugler, Catherine M. Ramsay, Wililam J. Simpson, Mark B. Driscoll
  • Patent number: 10098935
    Abstract: The instant disclosure provides aquaporin DNA tolerizing vaccines and methods of using such vaccines for treating individuals having neuromyelitis optica (NMO) and NMO spectrum disorders. Aspects of the methods include administering to the individual, in need thereof, an effective amount of an aquaporin DNA tolerizing vaccine to reduce one or more symptoms of NMO or an NMO spectrum disorder. Compositions and kits for practicing the methods of the disclosure are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: October 16, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence Steinman, Peggy P. Ho
  • Patent number: 9354225
    Abstract: The invention provides methods for detection in stored biological samples of PrPsc and other analytes that are present in exosomes.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: May 31, 2016
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Sergio Agustin Lizano-González, Lisa Ann Estey
  • Patent number: 8920334
    Abstract: The invention relates to an analysis method for determining a functional parameter of an organ of a human or animal individual by measuring the 13CO2 content in the air exhaled by the individual to which a substrate has been administered the reaction of which in the body of the individual enriches the air exhaled by the individual with 13CO2. The method is characterized by using a measuring device, the maximum reaction rate of the substrate in the body of the individual being determined via a change of the measured 13CO2 content in the air exhaled by the individual using zero-order enzyme kinetics. The invention also relates to an aqueous methacetin solution for use in said analysis method, the pH of the solution being greater 7.0. The invention also relates to a face mask (1) for use in the inventive method for separating the exhaled air from the air inhaled by an individual. Said face mask comprises a face mask body (2) and an air cushion (3) encircling the face mask body.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: December 30, 2014
    Assignees: Freie Universitaet Berlin, Charité Universitaetmedizin Berlin
    Inventors: Martin Stockmann, Bjön Riecke
  • Patent number: 8889102
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 18, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Sean J. Pittock
  • Patent number: 8822232
    Abstract: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis and mycoplasma associated diseases.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 2, 2014
    Inventor: Maria de Lourdes Higuchi
  • Patent number: 8759114
    Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 24, 2014
    Assignee: Stichting Voor de Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8668978
    Abstract: Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 11, 2014
    Assignee: Northeastern University
    Inventors: Asanterabi Malima, Ahmed Busnaina, Salome Siavoshi, Sivasubramanian Somu, Cihan Yilmaz, Tiziana Musacchio, Jaydev Upponi, Vladimir Torchilin
  • Patent number: 8642357
    Abstract: The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: February 4, 2014
    Assignee: Yale University
    Inventors: Jack A. Elias, Chun Geun Lee
  • Patent number: 8614103
    Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: December 24, 2013
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Glenn L. Stoller
  • Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Patent number: 8524508
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: September 3, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Thomas J Kryzer
  • Patent number: 8486401
    Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 16, 2013
    Assignee: Lay Line Genomics S.p.A.
    Inventor: Michal M. Novak
  • Patent number: 8470524
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: June 25, 2013
    Assignee: Theranos, Inc.
    Inventors: Ian Gibbons, Michael O'Connell
  • Patent number: 8278119
    Abstract: By detecting an antibody which immunologically reacts with amylase ?2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. For instance, detection of this antibody is carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 511 of human amylase ?2-A (SEQ ID NO: 1).
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: October 2, 2012
    Assignees: University of Yamanashi, Cosmic Corporation
    Inventors: Tetsuro Kobayashi, Toyoshi Endo, Atsushi Sakuraoka
  • Publication number: 20120149132
    Abstract: The present invention is to present an analyzing method for analyzing a target substance contained in a sample using a reagent containing magnetic particles. The method comprises steps of: (a) magnetically capturing magnetic particles in a container with a first magnetic force generating member arranged on a lower side of the container accommodating a liquid specimen containing the magnetic particles; (b) transferring the container to a target substance separating section after the step (a); and (c) in the target substance separating section, discharging a cleaning liquid into the container and aspirating a liquid in the container while magnetically capturing the magnetic particles in the container with a second magnetic force generating member.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Inventors: Hiroto Toyoshima, Kazunori Mototsu
  • Patent number: 8137991
    Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: March 20, 2012
    Assignees: The Cleveland Clinic Foundation, Case Western Reserve University
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Reganathan
  • Patent number: 8093068
    Abstract: Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a human germline framework database.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 10, 2012
    Assignee: Centocor, Inc.
    Inventors: Shizhong Chen, Shanrong Zhao
  • Patent number: 8075891
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: December 13, 2011
    Assignee: Amorfix Life Sciences Ltd.
    Inventor: Neil Cashman
  • Patent number: 8067247
    Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: November 29, 2011
    Assignee: Institut National de la Sante Et de la Recherche Medicale (INSERM)
    Inventors: Marie-Françoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
  • Patent number: 8048637
    Abstract: A diagnostic composition to detect antibodies in a sample obtained from an animal or human being infected by Trichinella, comprising at least one peptide containing a series of amino acids that form a continuous or discontinuous epitope recognized by sera from pigs infected with Trichinella.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: November 1, 2011
    Assignee: Prionics AG
    Inventors: Patrik Buholzer, Alex Raber, Paul Price, Daniel Zwald, Weldy Bonilla Pinschewer, Roger Marti, Jurg Weidmann, Christoph Stamm
  • Patent number: 8012744
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: September 6, 2011
    Assignee: Theranos, Inc.
    Inventors: Ian Gibbons, Michael O'Connell
  • Patent number: 8008034
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: August 30, 2011
    Assignee: Theranos, Inc.
    Inventors: Ian Gibbons, Michael O'Connell
  • Patent number: 7888133
    Abstract: The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrulline or an analogue thereof, and nonG is an amino acid other than glycine.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: February 15, 2011
    Assignee: Stichting Voor De Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 7842500
    Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swarn tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 30, 2010
    Assignee: Seikagaku Corporation
    Inventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
  • Patent number: 7833731
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: November 16, 2010
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Patent number: 7820394
    Abstract: The invention relates to ultrasensitive bioanalytical assays based on the use of high-gain catalytic chemical amplification methods. The ultrasensitive bioanalytical assays of the invention utilize high gain catalytic chemical amplification methods to detect the presence and to quantify the concentrations of target analytes labeled with specific binding reagents or biomarkers comprising a catalyst or a catalyst precursor.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: October 26, 2010
    Assignee: CatAssays
    Inventors: Mark Lelental, Henry J. Gysling
  • Patent number: 7767419
    Abstract: The invention provides a method to efficiently express high levels of a recombinant untagged NT-proBNP for use as a calibrator in NT-proBNP immunoassays.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 3, 2010
    Assignee: Nexus DX, Inc.
    Inventors: Azhar Alvi, William Yajima, Roshana Sikora, George Jackowski, Mee-Ra Hong
  • Patent number: 7700306
    Abstract: Provided is a method for characterizing an analyte by matrix assisted laser desorption ionization (MALDI) mass spectrometry, which method comprises: (a) labelling the analyte with a light-absorbing label that absorbs light at a pre-determined frequency, to form a labelled analyte; (b) embedding the labelled analyte in a matrix formed from at least one compound that absorbs light, to form an embedded labelled analyte; (c) desorbing the embedded labelled analyte by exposing it to light having the pre-determined frequency, to form a desorbed analyte; and (d) detecting the desorbed analyte by mass spectrometry to characterize the analyte.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: April 20, 2010
    Assignee: Electrophoretics Limited
    Inventors: Andrew H. Thompson, Christian Hamon, Karsten Kuhn, Markus Meyer, Schafer Juergen, Thomas Neumann
  • Patent number: 7687238
    Abstract: Methods for (1) evaluating feline kidney function by determining ghrelin level in feline tissue or biofluid and correlating the ghrelin level directly to kidney function and (2) diagnosing kidney disease in a feline comprises determining an observed ghrelin level in a tissue or biofluid of the feline and comparing the observed ghrelin level to a reference ghrelin level indicative of normal kidney function, wherein an observed level lower than the reference level is indicative of kidney disease or susceptibility thereto.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: March 30, 2010
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Kim Gene Friesen, Ryan Michael Yamka
  • Patent number: 7629130
    Abstract: Methods for detecting and quantifying phosphoinositide lipids in a sample are provided, together with novel SidC- and SdcA-derived polypeptide fragments, or fusion proteins comprising such fragments that may be effectively employed as PI(4)P probes in biochemical and cell biological assays. Applications of the disclosed probes include: (i) detection and quantification of PI(4)P in vitro; and (ii) staining of intracellular compartments in live or fixed eukaryotic cells.
    Type: Grant
    Filed: September 23, 2006
    Date of Patent: December 8, 2009
    Assignee: Eidgenossisch Technische Hochschule Zurich Eth
    Inventor: Hubert Hilbi
  • Publication number: 20090291509
    Abstract: To enable successive measurement of samples by using one piezoelectric sensor. An adsorption layer provided in a piezoelectric sensor is an adsorption layer in which protein and an immunoglobulin are stacked in this order from the bottom. The immunoglobulin has a property of separating from protein when coming into contact with an acid liquid, and therefore, when the immunoglobulin as the adsorption layer is brought into contact with the acid liquid after capturing a substance to be sensed, the immunoglobulin is separated from the protein. Then, the adsorption layer is again formed by the supply of a new immunoglobulin, which enables the successive measurement of samples.
    Type: Application
    Filed: May 18, 2009
    Publication date: November 26, 2009
    Applicant: NIHON DEMPA KOGYO CO., LTD.
    Inventor: Shunichi Wakamatsu
  • Patent number: 7604954
    Abstract: Methods for (1) evaluating feline kidney function by determining ghrelin level in feline tissue or biofluid and correlating the ghrelin level directly to kidney function and (2) diagnosing kidney disease in a feline comprises determining an observed ghrelin level in a tissue or biofluid of the feline and comparing the observed ghrelin level to a reference ghrelin level indicative of normal kidney function, wherein an observed level lower than the reference level is indicative of kidney disease or susceptibility thereto.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: October 20, 2009
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Kim Gene Friesen, Ryan Michael Yamka
  • Patent number: 7547506
    Abstract: The present invention provides an assay for detection of M. bovis-infected animals. A tracer, comprising a peptide of M. bovis protein MPB70 conjugated to a fluorophore, is added to a serum sample from an animal to form a mixture. The fluorescence polarization of the mixture in then measured and compared to the fluorescence polarization of a control. The present invention further provides a tracer for use in fluorescence polarization assay to detect antibodies specific for M. bovis. The tracer comprises a peptide of M. bovis protein MPB70 conjugated to a fluorophore, such that the tracer is able to bind to antibodies specific for M. bovis to produce a detectable change in fluorescence polarization.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: June 16, 2009
    Assignees: Diachemix LLC, Her Majesty the Queen in Right of Canada, as represented by the Canadian Food Inspection Agency
    Inventors: Om P. Surujballi, Anna Romanowska, Michael E. Jolley, Mohammad Sarwar Nasir
  • Publication number: 20080213922
    Abstract: There is provided a method for the identification of antigens recognized by a given antibody. In particular the method provides for characterization of the epitope recognized by the antibody and for purification based on the physico-chemical properties of the antigen. The characterization facilitates subsequent analysis of the antigen for identification purposes.
    Type: Application
    Filed: April 4, 2006
    Publication date: September 4, 2008
    Inventor: Francina C. Chahal
  • Patent number: 7399645
    Abstract: The invention pertains to bioconjugation systems comprising sterically constrained cis-diols and borates.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: July 15, 2008
    Assignee: Applera Corporation
    Inventors: Ricky F. Baggio, Alison L. Sparks, Rouh-Rong Juo, Jaime E. Arenas
  • Patent number: 7399644
    Abstract: An assay method for determining presence of a target antibody or antigen in a specimen qualitatively or quantitatively by mixing the specimen with an antigen or antibody immunologically reactive with the target antibody or antigen, and assaying the level of the immunological agglutination reaction, wherein the reactive antigen or antibody is effectively immobilized on the carrier via an amino acid sequence capable of binding to the carrier.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: July 15, 2008
    Assignee: Canon Kabushiki Kaisha
    Inventors: Tsutomu Honma, Tetsuya Yano, Tsuyoshi Nomoto, Shinya Kozaki
  • Patent number: 7399470
    Abstract: A sandwich immunoassay kit for detecting ciguatoxins based on a combination of two anti-ciguatoxin CTX3C monoclonal antibodies produced by hybridomas, 3D11 (deposited at IPOD, AIST under accession number FMRM PB-8293) and 10C9 (FMRM PB-8292). In particular, one of the antibodies is labeled and each of them binds specifically to a different site of ciguatoxin CTX3C.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: July 15, 2008
    Assignee: Japan Science and Technology Agency
    Inventors: Masahiro Hirama, Hiroki Oguri, Ikuo Fujii, Takeshi Tsuburaya
  • Patent number: 7279295
    Abstract: The present invention relates to a novel allergen from timothy grass (Phleum pretense) pollen, Phl p11 as disclosed in SEQ ID NO:2, and use thereof as a reagent and in a diagnositic kit as well as for immunotherapy.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: October 9, 2007
    Assignee: Phadia AB
    Inventors: Asa Marknell Dewitt, Verena Niederberger, Pirjo Lehtonen, Susanne Spitzauer, Wolfgang R. Sperr, Peter Valent, Rudolf Valenta, Jonas Lidholm
  • Patent number: 7271252
    Abstract: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: September 18, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Mitali Ghoshal, Lili Arabshahi
  • Patent number: 7247502
    Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: July 24, 2007
    Assignee: Nabi Biopharmaceuticals
    Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
  • Patent number: 7183108
    Abstract: The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fermented dairy products used for regulating inflammatory response and non-specific immunity.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: February 27, 2007
    Assignee: Compagnie Gervais Danone
    Inventors: Chantal Cayuela, Nathalie Dugas, Eric Postaire
  • Patent number: 7157234
    Abstract: A microscale binding assay, analyte binding array, and kits are disclosed, which exploit the mass action law to harvest analyte from a liquid sample. This is achieved by fabrication of sorbent zones having up to ten times the binding capacity per unit area generally obtained on polystyrene microtiter plates. The resulting arrays substantially deplete the liquid solution of analyte during incubation. Accordingly, the assays respond to total mass of analyte in the sample, not analyte concentration. This approach, coupled with direct fluorescence detection in the NIR, yields maximal signal intensity and low background for optimal sensitivity.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: January 2, 2007
    Assignee: Beckman Coulter, Inc.
    Inventors: Robert J. Obremski, John W. Silzel, Tsong-Tseh Tsay, Bibijana Cercek, Charles L. Dodson, Tung Rung Wang, Yagang Liu, Zhou Shaomin
  • Patent number: 7138244
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: November 21, 2006
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Paul A. Barstad, Gilbert M. Iverson
  • Patent number: 7070941
    Abstract: The invention provides methods and compositions for azide tagging of biomolecules. In one embodiment of the invention, proteins are tagged by metabolic incorporation of prenylated azido-analog substrates. Examples of such analogs are azido farnesyl diphosphate and azido farnesyl alcohol. The azido moiety in the resulting modified proteins provides an affinity tag, which can be chemoselectively captured by an azide-specific conjugation reaction, such as the Staudinger reaction, using a phosphine capture reagent. When the capture agent is biotinylated, the resulting conjugates can be detected and affinity-purified by streptavidin-linked- HRP and streptavidin-conjugated agarose beads, respectively. The invention allows detection and isolation of proteins with high yield, high specificity, and low contamination without harsh treatment of proteins.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: July 4, 2006
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yingming Zhao, John R. Falck
  • Patent number: 7063980
    Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of mutans streptococci by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of mutans streptococci in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and mutans streptococci from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: June 20, 2006
    Assignee: GC Corporation
    Inventor: Atsushi Tachino
  • Patent number: 7018616
    Abstract: The present invention provides an assay for detection of serum antibodies to M. paratuberculosis. A tracer, comprising a carbohydrate antigen isolated from M. paratuberculosis that is conjugated to a fluorophore, is added to a serum sample from an animal to form a mixture. The fluorescence polarization of the mixture is then measured. The presence of serum antibodies to M. paratuberculosis is indicated by a fluorescence polarization value of the mixture that is higher than the fluorescence polarization value of a control. The present invention further provides a tracer for use in a fluorescence polarization assay for antibodies specific for M. paratuberculosis. The tracer comprises a carbohydrate antigen isolated from M. paratuberculosis and conjugated to a fluorophore, such that the tracer is able to bind to antibodies specific for M. paratuberculosis to produce a detectable change in fluorescence polarization.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: March 28, 2006
    Assignees: Diachemix LLC, Her Majesty the Queen in Right of Canada as represented by the Canadian Food Inspection Agency
    Inventors: Om P. Surujballi, Kathryn Irene Stilwell
  • Patent number: 6986994
    Abstract: An antibody is provided which specifically recognizes and binds to INGAP protein. The antibody is used in competitive binding assays for quantitation of INGAP in biological samples. The assay can be performed on a solid support or in a suspension.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: January 17, 2006
    Assignee: GMP Endotherapeutics, Inc.
    Inventors: Aaron I. Vinik, David A. Taylor-Fishwick
  • Patent number: 6967107
    Abstract: The present invention describes carbamic acid ester-derived and valeric acid ester-derived polyfunctional cross-linker molecules, and methods for their synthesis and use. The inclusion of polymeric moieties such as poly(alkylene oxide) in the cross-linkers of the present invention can provide advantageous solubility properties in aqueous environments. Such cross-linkers may be used to form conjugates for use in a variety of assay formats.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 22, 2005
    Assignee: Biosite, Inc.
    Inventors: Kenneth F. Buechler, Mariusz G. Banaszczyk, Joseph Barry Noar